Tonix Pharmaceuticals Holding Corp.
TNXPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Noble Capital Markets | maintain | Outperform | Mar 20, 2025 |
| Alliance Global Partners | maintain | Buy | Jul 22, 2024 |
| Alliance Global Partners | maintain | Buy | Aug 1, 2023 |
| Alliance Global Partners | maintain | Buy | Jun 2, 2023 |
| Alliance Global Partners | maintain | Buy | Jan 12, 2023 |
| Noble Capital Markets | maintain | Outperform | Apr 18, 2022 |
| Alliance Global Partners | maintain | Buy | Aug 31, 2021 |
| Alliance Global Partners | maintain | Buy | Aug 11, 2021 |
| Alliance Global Partners | maintain | Buy | Feb 25, 2021 |
| Oppenheimer | maintain | Outperform | Nov 18, 2019 |
| Cantor Fitzgerald | maintain | Buy | Nov 18, 2019 |
| Roth Capital | downgrade | Buy →Neutral | Nov 18, 2019 |
| Roth Capital | upgrade | Neutral →Buy | Nov 18, 2019 |
| B. Riley FBR | downgrade | Buy →Neutral | Nov 18, 2019 |
| Roth Capital | upgrade | Neutral →Buy | Apr 18, 2019 |
| Roth Capital | downgrade | Buy →Neutral | Jul 27, 2018 |
| B. Riley FBR | downgrade | Buy →Neutral | Jul 27, 2018 |
| B. Riley FBR | maintain | Buy | Jun 6, 2018 |
| Roth Capital | upgrade | Neutral →Buy | Aug 18, 2017 |
| Roth Capital | downgrade | Buy →Neutral | Sep 7, 2016 |
| Cantor Fitzgerald | downgrade | Buy →Hold | Sep 7, 2016 |
| Cantor Fitzgerald | maintain | Speculative Buy →Buy | Jun 2, 2016 |
| Cantor Fitzgerald | maintain | Buy →Speculative Buy | Feb 17, 2016 |
| Cantor Fitzgerald | maintain | Buy | Feb 17, 2016 |
| Oppenheimer | maintain | Outperform | Feb 17, 2016 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-2.44 | $-2.64 | $13.5M | $7.7M |
| May 11, 2026 | $-2.93 | $-2.54 | $6.9M | $6.1M |
| Mar 12, 2026 | $-3.98 | $-3.16 | $5.4M | $3.0M |
| Nov 10, 2025 | $-3.59 | $-3.59 | $3.3M | $2.3M |
| Aug 12, 2025 | $-3.86 | $-3.10 | $2.0M | $2.4M |
| May 12, 2025 | $-2.84 | $-3.23 | $2.4M | $2.6M |
| Mar 18, 2025 | $-9.77 | $-6.23 | $2.6M | $3.2M |
| Nov 12, 2024 | $-23.00 | $-203.00 | $2.8M | $3.1M |
News
BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that management will present and host 1x1 meetings at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston, Massachusetts on Tuesday, November 10, 2026.
BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the appointment of George Lederman, Ph.D.
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix commercially launched TONMYA® in November 2025, the first fibromyalgia drug for adults in the U.S. in over 15 years approved by the U.S. Food and Drug Administration (FDA) BERKELEY HEIGHTS, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a…
BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report third quarter 2026 financial results and operational highlights on Monday, November 9, 2026, at 8:30 a.m.
A new fibromyalgia drug just reached tens of millions of Medicare members, and patients are already assuming their costs are settled. One document their insurer controls will tell a very different story before open enrollment closes December 7.
BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thaila…
BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, “Vectored Vaccine Platforms: From Design to Improving …
WAVE Life Sciences (NASDAQ: WVE - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations. Volatility and Risk WAVE Life Sciences
New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second…
Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and Voyager Therapeutics (NASDAQ: VYGR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability. Valuation and Earnings This table compares Tonix
Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.
BERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately.
BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor's 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York.
Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.
Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch. Revenue also included approximately $2.5 million from migraine products
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives) First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD) Phase 2 adaptive field study of TNX-4800 for the prevention of Lyme disease in the U.S…